Skip to main content

DEVELOPMENT PIPELINE

Explore our Active Programs

BRAIN-DRUG DELIVERY TECHNOLOGIES

Psycheceutical is currently developing products for neuropsychiatric and neurocognitive disorders which are at clinical and pre-clinical stages.

DEVELOPMENT PIPELINE

Our goal is to employ our patented brain-drug delivery strategies to clinically advance FDA-approved psychedelics and Generation 3 therapeutics for neuropsychiatric and neurocognitive disorders in the treatment of mental health and mood disorders.

PSY-007

KETAMINE
INDICATION:

Post Traumatic Stress Disorder (PTSD)

 

STAGE:

Phase I Clinical Trials

 

PSY-007

KETAMINE
INDICATION:

Complex Regional Pain Syndrome (CRPS)

 

STAGE:

CMC

 

PSY-034

UNDISCLOSED
INDICATION:

Addiction

 

STAGE:

CMC

 

PSY-058

UNDISCLOSED
INDICATION:

Parkinson’s Disease

 

STAGE:

Preclinical

 

Our additional IP uniquely focuses on development of brain-drug delivery to combat traumatic brain injuries as we seek to improve functional outcomes for those who suffer from TBI-related conditions.

PSY-311

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

CMC

 

PSY-322

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

PSY-345

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

Discover Our Drug

Delivery Technologies